HOB Biotech Group (HOB) is an innovative in-vitro diagnostic company founded by overseas returnees, John Li, with education and decades of industrial experience in the United States. HOB specialize in providing innovative and efficient diagnosis tools to laboratories and hospitals for the improvement of allergy and autoimmune disease patient care. HOB are committed to providing "affordable and reliable" diagnostic products for patients worldwide.
Since established in 2009, with years of dedicated research investment and efforts, HOB has gradually become a market leader in allergy diagnostics and a rising star in autoimmune diagnostics in China. We have established a large-scale, ISO 13485 certified manufacturing facility in Suzhou, China, producing high quality products ranging from line immuno assay (BioLINE) to enzyme-linked immunosorbent assay (BioLISA) and more advanced chemiluminescence microparticle immuno assay (BioCLIA). HOB has further established world-class R&D centers in California, US, with a well experienced product development team and led by scientists with education and decades of R&D experience in IVD diagnosis.
HOB adhere to the customer needs and continuously improve our service capabilities. We have built a marketing service team which covers 34 provinces/municipalities all across China to provide professional technical services in a timely manner.
Based in Asia, Influencing the World
HOB's mission is to develop and offer customers "affordable and reliable" products in allergy and autoimmune in vitro diagnostics, with state-of-art technologies, topnotch quality, and competitive prices. As a leading manufacturer with strong R&D capability, HOB is expanding its global influence by forming strategic alliances with companies worldwide to provide advanced technology and the most competitive products.
The Successful IPO of HOB on Shanghai Stock Exchange
On Jan.13th 2021, HOB completed its IPO and is formally listed on Shanghai Stock Exchange, abbreviated as "浩欧博 HOB". HOB shares are traded underthe Shanghai Stock Exchange code "688656". This is a big milestone in HOB's history. Thesuccessful IPO will help us pursue our long term vision of becoming a world-class company in the allergy and autoimmune IVD industry. HOB has raised CNY 556 million (equivalent to 70 million euros / 86 million USD) with the IPO. The fund will be used to boost our global capability and capacity, providing resources to execute our business strategies, furtherdevelop our R&D pipeline and deliver better solutions to our customers and patients, and building a stronger brand.
Furthermore, HOB are strivedto develop innovated diagnostic products, specialized in autoimmunity and allergy with expanding of our current product menu. We are committed to continuously enhance our service quality and expand service network worldwide.
| Full name | HOB BIOTECH GROUP CORP.,LTD. |
|---|---|
| Abbreviations | HOB Biotech |
| Code | 688656 |
| Founded | 2009-06-08 |
| Listing | 2021-01-13 |
| Domicile | SUITE 101,BIOBAY BUILDING C6, 218 XINGHU ROAD,SUZHOU INDUSTRIAL PARK,JIANGSU,CHINA |
| Website | http://www.hob-biotech.com |
| jshob@hob-biotech.com | |
| STAR Theme | Biomedicine |
| CSRC Sector | Manufacturing |
| Has weighted voting rights structure? | No |
| 2020 | 2019 | 2018 | |
|---|---|---|---|
| Earnings Per Share | 1.20 | 1.35 | 0.88 |
| R&D expenditure as a % of operating revenue | 10.88% | 9.82% | 11.99% |
| Operating Revenue | 22,185.69 | 25,912.74 | 20,144.62 |
| Net Income | 5,661.76 | 6,383.85 | 4,015.44 |
| 2020 | 2019 | 2018 | |
|---|---|---|---|
| Operating Revenue | 221.86 | 259.13 | 201.45 |
| Operating Costs | 172.57 | 189.21 | 144.93 |
| Operating Income | 65.10 | 70.05 | 49.16 |
| Pretax Income | 65.10 | 73.56 | 46.71 |
| Income Tax | 8.49 | 9.72 | 6.56 |
| Net Income | 56.62 | 63.84 | 40.15 |
| 2020 | 2019 | 2018 | |
|---|---|---|---|
| Assets | |||
| Current Assets-Total | 158.65 | 176.49 | 140.38 |
| Non-current Assets-Total | 137.76 | 106.69 | 84.84 |
| Total Assets | 296.41 | 283.18 | 225.22 |
| Liabilities | |||
| Current Liabilities-Total | 63.23 | 122.89 | 77.60 |
| Non-current Liabilities-Total | 26.80 | 10.65 | 14.50 |
| Total Liabilities | 90.02 | 133.54 | 92.10 |
| Stockholder's Equity | |||
| Share Capital | 115.95 | 115.95 | 115.95 |
| Retained Profits | 90.44 | 33.69 | 17.17 |
| Minority Interests | 0 | 0 | 0 |
| Total Owners' Equity | 206.39 | 149.64 | 133.12 |
| 2020 | 2019 | 2018 | |
|---|---|---|---|
| Net Cash Flows-Operating | 58.22 | 68.57 | 46.51 |
| Net Cash Flows-Investing | -35.03 | -33.75 | -25.39 |
| Net Cash Flows-Financing | -55.25 | -10.55 | 31.36 |
| Name | No. of Shares Held (mn) | % of Shares Held |
|---|---|---|
| 海瑞祥天生物科技（集团）有限公司 | 35.10 | 55.66% |
| 苏州外润投资管理合伙企业（有限合伙） | 7.73 | 12.26% |
| 广州市金阖股权投资管理合伙企业（有限合伙） | 2.07 | 3.28% |
| 华泰浩欧博家园1号科创板员工持股集合资产管理计划 | 1.58 | 2.5% |
| 福州泰弘景晖股权投资合伙企业（有限合伙） | 0.98 | 1.55% |
| 华泰创新投资有限公司 | 0.73 | 1.15% |
| 珠海泰弘景晖股权投资合伙企业（有限合伙） | 0.68 | 1.08% |
| 中国银行股份有限公司－博时健康成长主题双周定期可赎回混合型证券投资基金 | 0.53 | 0.83% |
| 招商银行股份有限公司－富国科创板两年定期开放混合型证券投资基金 | 0.53 | 0.83% |
| 平潭建发拾号股权投资合伙企业（有限合伙） | 0.51 | 0.82% |
All information contained herein is provided by the underlying company itself and is for informational purposes only, and nothing contained herein should be construed as investment advice, either on behalf of a particular security or an overall investment strategy. The Shanghai Stock Exchange does not guarantee its accuracy and reliability and shall under no circumstance be responsible or liable for any error or for any loss directly or indirectly arising from any inaccuracy or omission or from any decision, action or non-action based on or in reliance upon the information herein.
Users may view and download the information herein for personal and non-commercial use free of charge subject to the laws of the People's Republic of China and the Legal Statement. No part of the information herein may be copied, downloaded, stored in a retrieval system or transmitted in any form or by any means, rented, displayed, performed, reproduced, photocopied, altered, sold, broadcast, published or otherwise in whole or in part in any manner for commercial purposes, without the prior written consent of the Shanghai Stock Exchange.
Users are hereby reminded that the Legal Statement represents your legally binding agreement with the Shanghai Stock Exchange. By accessing or using this website, you are also signifying your agreement with and acceptance of all the contents in the Legal Statement. The Shanghai Stock Exchange reserves the right to amend and interpret the Legal Statement.